What the changes say
- Sutro Biopharma restructured in March and September 2025, shifting entirely to third-party contract manufacturers for product supply.
- The company faces novel regulatory uncertainties because no product manufactured on a cell-free platform has yet received FDA approval.
- Risks highlight reliance on third-party suppliers, potential impacts of U.S.-China trade relations, and intense biopharmaceutical competition.
What changed since the prior 10-K
New
- NewRisks Related to Our Business
FDA. Before obtaining regulatory approval for the commercial distribution of our product candidates, we or an existing or future collaborator must conduct extensive preclinical tests and clinical trials to demonstrate the safety and efficacy in humans of our product candidates
We may lack the financial resources to continue developing product candidates if clinical trials are delayed or fail.
- NewRisks Related to Our Business
miss expected deadlines, our development program could be delayed with potentially material and adverse effects on our business, financial condition, results of operations and prospects
We rely on third-party investigators and CROs to conduct preclinical and clinical trials over which we have limited control.
- NewRisks Related to Our Business
Following our March 2025 and September 2025 restructurings, we use a product supply approach wherein all elements of our product candidates, including raw and intermediate materials, are manufactured at qualified third-party CMOs
Following our 2025 restructurings, we rely entirely on third-party contract manufacturers and sole suppliers for raw materials.
- NewRisks Related to Our Business
U.S.-China trade relations may adversely impact our supply chain operations and business
U.S. and Chinese trade policies and tariffs could increase the cost or restrict the import of components from China.
- NewRisks Related to Our Business
If we are able to adequately validate and scale-up the manufacturing process for our product candidates with a contract manufacturer, we will still need to negotiate with such contract manufacturer an agreement for commercial supply and it is not certain we will be able to come to agreement on terms acceptable to us
Our contract manufacturers have limited experience producing cGMP batches of our complex biologic product candidates.
- NewRisks Related to Our Business
more effective, our ability to develop and successfully commercialize product candidates may be adversely affected
We face intense competition from multinational biopharmaceutical companies with significantly greater financial and human resources.
- NewRisks Related to Our Business
management's attention, governmental investigations, lawsuits, and the expenditure of significant capital and other resources
Employee or vendor use of generative artificial intelligence could result in the leakage of sensitive company information.
- NewRisks Related to Intellectual Property
develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability
Disputes regarding licensing agreements and intellectual property ownership could prevent us from achieving profitability.
- NewRisks Related to Government Regulation
meet certain safe-use criteria and requiring treated patients to enroll in a registry. These limitations and restrictions may limit the size of the market for the product and affect reimbursement by third-party payors
Conflicting advice from foreign regulatory authorities may complicate our international clinical development and approval processes.
- NewRisks Related to Government Regulation
We may also combine the use of our product candidates with other investigational or approved therapies that may cause separate adverse events or events related to the combination
Combining our product candidates with other therapies may cause unforeseen adverse events or regulatory penalties.
- NewRisks Related to Government Regulation
to enhance the balance of access and verification of benefit for therapies available to patients with cancer and hematologic malignancies
The FDA may require expensive post-approval studies with strict completion deadlines and ongoing progress reports.
- NewRisks Related to Our Common Stock
inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, results of operations and financial condition
Our bylaws designate federal district courts as the exclusive forum for resolving Securities Act complaints.
- NewRisks Related to Our Common Stock
If we fail to maintain compliance with Nasdaq’s minimum listing requirements, our common stock will be subject to delisting. Our ability to publicly or privately sell equity securities and the liquidity of our common stock could be adversely affected if our common stock is delisted
- NewRisks Related to Our Common Stock
On December 17, 2025, we regained compliance with Nasdaq Listing Rule 5450(a)(1) following our reverse stock split
Dropped
- DroppedRisks Related to Our Business
the availability of alternative effective treatments for the disease indications our product candidates are intended to treat and the relative risks, benefits and costs of those treatments
- DroppedRisks Related to Our Business
commercialize therapeutics using our novel and unprecedented iADC or ADC2 technology. We may never receive approval to market and commercialize any potential iADC or ADC2 product candidate
- DroppedRisks Related to Our Business
responsibilities and requirements. Any adverse development or delay in our preclinical studies or clinical trials as a result of our reliance on third parties could have a material and adverse effect on our business, financial condition, results of operations and prospects
- DroppedRisks Related to Our Business
manufacturer an agreement for commercial supply and it is not certain we will be able to come to agreement on terms acceptable to us
- DroppedRisks Related to Our Business
Our success will depend partially on our ability to develop and protect therapeutics that are safer and more effective than competing products. Our commercial opportunity and success will be reduced or eliminated if competing products are safer, more effective, or less expensive than the therapeutics we develop
- DroppedRisks Related to Our Business
below the market price of our common stock, particularly after the expiration of the lock-up agreements described herein
- DroppedRisks Related to Our Business
generated in tax years beginning after December 31, 2017, may be carried forward indefinitely, but the deductibility of such federal net operating losses, is limited to 80% of taxable income (without regard to certain deductions)
- DroppedRisks Related to Intellectual Property
intellectual property rights such as patents, as appropriate, the process of obtaining patents is time consuming, expensive and sometimes unpredictable
- DroppedRisks Related to Intellectual Property
claims against us or our licensors or collaborators. We or our licensors or collaborators may not prevail in any lawsuits that we or our licensors or collaborators initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful
- DroppedRisks Related to Government Regulation
While there have been legislative and judicial efforts to modify, repeal or otherwise invalidate all or certain aspects of the ACA or its implementing regulations, the ACA remains in effect in its current form. It is unclear how any such efforts in the future will impact the ACA or our business
- DroppedRisks Related to Government Regulation
Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of patients and limited duration of exposure, rare and severe side effects of our product candidates may only be uncovered with a significantly larger number of patients exposed to the product candidate
Risks related to alternative treatments and market size estimates.
- DroppedRisks Related to Our Common Stock
establish advance notice requirements for nominations for election to our board or for proposing matters that can be acted upon by stockholders at annual stockholder meetings
Reworded
- 98% rewrittenRisks Related to Our Business
Dual-payload ADC technology is novel, which makes it difficult to predict the time, risks and cost of development and of subsequently obtaining regulatory approval of these potential product candidates
Updated terminology from iADC and ADC2 technology to novel dual-payload ADC technology.
Was: iADC and ADC2 are novel technologies, which makes it difficult to predict the time, risks and cost of development and of subsequently obtaining regulatory approval of these potential product candidates
- 94% rewrittenRisks Related to Government Regulation
We may face difficulties from healthcare legislative reform measures
Maintained general language regarding healthcare legislative reform measures and pricing regulations.
- 90% rewrittenRisks Related to Our Business
Our ability to use net operating loss carryforwards to offset taxable income could be limited
Added specific details regarding the 80% taxable income limitation on post-2017 federal net operating losses.
- 81% rewrittenRisks Related to Intellectual Property
We may not be able to protect our intellectual property rights throughout the world
Clarified international patent protection costs and the difficulty of enforcing patents outside the United States.
- 80% rewrittenRisks Related to Our Business
we may not realize the full commercial potential of any product candidates that receive marketing approval if, among other reasons, we are unable to appropriately identify patients with the specific patient selection criteria targeted by our product candidates
Expanded patient selection criteria to include patient selection schema beyond genetic testing.
Was: we may not realize the full commercial potential of any product candidates that receive marketing approval if, among other reasons, we are unable to appropriately identify patients with the specific genetic alterations targeted by our product candidates
- 76% rewrittenRisks Related to Our Business
To date, no product developed on a cell-free manufacturing platform has received approval from the FDA, so the requirements for the manufacturing of products using our XpressCF ® and XpressCF+ ® platforms are uncertain
Added details on the lack of FDA approvals for cell-free manufacturing platforms using XpressCF and XpressCF+.
- 74% rewrittenRisks Related to Our Business
In addition, job candidates and existing employees often consider the value of the stock awards they receive
Incorporated both the March 2025 and September 2025 restructurings and workforce reductions into employee retention risks.
- 74% rewrittenRisks Related to Our Business
Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flows, financial condition or results of operations
Added reference to the One Big Beautiful Bill Act restoring immediate deductibility of domestic R&D expenditures for 2025.
- 71% rewrittenRisks Related to Our Business
in the event of approval to market and commercialize a product candidate, an inability to meet commercial demands for our products
- 70% rewrittenRisks Related to Government Regulation
we disseminate false or misleading promotional materials relating to the relevant product candidate
- 68% rewrittenRisks Related to Government Regulation
injunctions or the imposition of civil or criminal penalties
- 61% rewrittenRisks Related to Our Common Stock
In addition, Section 203 of the DGCL may discourage, delay or prevent a change in control of our company. Section 203 imposes certain restrictions on mergers, business combinations and other transactions between us and holders of 15% or more of our common stock
- 56% rewrittenRisks Related to Our Common Stock
Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations
- 53% rewrittenRisks Related to Our Business
general economic, industry and market conditions, including market volatility, high levels of inflation, changes in interest rates, changes in tariffs and trade restrictions, uncertainty with respect to the federal debt ceiling and budget and government shutdowns
Was: general economic, industry and market conditions, including market volatility, high levels of inflation, changes in interest rates, changes in tariffs and trade restrictions, uncertainty with respect to the federal debt ceiling and budget and potential government shutdowns related thereto
- 52% rewrittenRisks Related to Government Regulation
If we decide to seek Fast Track Designation or Breakthrough Therapy Designation by the FDA for any product candidate, even if successful, it may not lead to a faster development or regulatory review or approval process
Was: If we decide to seek Fast Track Designation by the FDA for any product candidate, even if successful, it may not lead to a faster development or regulatory review or approval process
- 48% rewrittenRisks Related to Government Regulation
If any of our product candidates receives marketing approval and we or others later identify undesirable side effects caused by the product candidates, our ability to market and derive revenue from the product candidates could be compromised
- 46% rewrittenRisks Related to Our Business
Failure to successfully validate, develop and obtain regulatory approval for companion diagnostics for our product candidates could harm our drug development strategy and operational results
- 40% rewrittenRisks Related to Intellectual Property
If we fail to comply with our obligations under any license, collaboration or other agreements, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our product candidates or we could lose certain rights to grant sublicenses
- 31% rewrittenRisks Related to Our Business
Price controls imposed in either the U.S. or foreign markets may adversely affect our future profitability
- 30% rewrittenRisks Related to Our Business
We or our collaborators’ inability to complete development of or commercialize our product candidates or significant delays in doing so due to one or more of these factors, could have a material and adverse effect on our business, financial condition, results of operations and prospects
- 29% rewrittenRisks Related to Our Common Stock
We may be subject to securities litigation, which is expensive and could divert management attention
- 29% rewrittenRisks Related to Our Business
Interim, top-line, or preliminary data from our clinical trials that we announce may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data
- 26% rewrittenRisks Related to Intellectual Property
If we are not able to obtain, maintain and enforce sufficient patent and other intellectual property protection for our technologies or product candidates, development and commercialization of our product candidates may be adversely affected
- 25% rewrittenRisks Related to Government Regulation
If in the future we are unable to establish U.S. or global sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates, we may not be successful in commercializing our product candidates if they are approved and we may not be able to generate any revenue
- 24% rewrittenRisks Related to Our Business
Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties
- 24% rewrittenRisks Related to Government Regulation
We and/or our collaborators may be unable to obtain, or may be delayed in obtaining, U.S. or foreign regulatory approval and, as a result, unable to commercialize our product candidates
- 23% rewrittenRisks Related to Our Business
Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
- 21% rewrittenRisks Related to Our Business
We may not be successful in our efforts to use our XpressCF ® and XpressCF+ ® platforms to expand our pipeline of product candidates and develop marketable products
- 21% rewrittenRisks Related to Our Business
We expect we will need to grow our organization in the future, and we may experience difficulties in managing our growth and expanding our operations
Was: We will need to grow our organization, and we may experience difficulties in managing our growth and expanding our operations
All 83 risk factors
Headings as the filing states them, in filing order.
Risks Related to Our Business
- 01We are a clinical stage oncology company. Biotechnology product development is a highly speculative undertaking and involves a substantial degree of risk
- 02general economic, industry and market conditions, including market volatility, high levels of inflation, changes in interest rates, changes in tariffs and trade restrictions, uncertainty with respect to the federal debt ceiling and budget and government shutdowns53% rewritten
- 03FDA. Before obtaining regulatory approval for the commercial distribution of our product candidates, we or an existing or future collaborator must conduct extensive preclinical tests and clinical trials to demonstrate the safety and efficacy in humans of our product candidatesNew
- 04We or our collaborators’ inability to complete development of or commercialize our product candidates or significant delays in doing so due to one or more of these factors, could have a material and adverse effect on our business, financial condition, results of operations and prospects30% rewritten
- 05achieving commercially relevant success in the market post approval
- 06We could encounter delays if prescribing physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles
- 07If we do not achieve our projected development goals in the timeframes we anticipate and project, the commercialization of our products may be delayed and our stock price may decline
- 08Our approach to the discovery and development of our therapeutic treatments is based on novel technologies, including unprecedented dual-payload ADC technology, which includes Immunostimulatory ADCs, that are unproven and may not result in marketable products
- 09Results of preclinical studies and early clinical trials may not be predictive of results of future clinical trials
- 10Interim, top-line, or preliminary data from our clinical trials that we announce may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data29% rewritten
- 11The market may not be receptive to our product candidates, and we may not generate any future revenue from the sale or licensing of product candidates
- 12Dual-payload ADC technology is novel, which makes it difficult to predict the time, risks and cost of development and of subsequently obtaining regulatory approval of these potential product candidates98% rewritten
- 13collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates
- 14We may not successfully engage in strategic transactions, including any additional collaborations we seek, which could adversely affect our ability to develop and commercialize product candidates, impact our cash position, increase our expenses and present significant distractions to our management
- 15To date, no product developed on a cell-free manufacturing platform has received approval from the FDA, so the requirements for the manufacturing of products using our XpressCF ® and XpressCF+ ® platforms are uncertain76% rewritten
- 16miss expected deadlines, our development program could be delayed with potentially material and adverse effects on our business, financial condition, results of operations and prospectsNew
- 17Following our March 2025 and September 2025 restructurings, we use a product supply approach wherein all elements of our product candidates, including raw and intermediate materials, are manufactured at qualified third-party CMOsNew
- 18in the event of approval to market and commercialize a product candidate, an inability to meet commercial demands for our products71% rewritten
- 19U.S.-China trade relations may adversely impact our supply chain operations and businessNew
- 20If we are able to adequately validate and scale-up the manufacturing process for our product candidates with a contract manufacturer, we will still need to negotiate with such contract manufacturer an agreement for commercial supply and it is not certain we will be able to come to agreement on terms acceptable to usNew
- 21We may not be successful in our efforts to use our XpressCF ® and XpressCF+ ® platforms to expand our pipeline of product candidates and develop marketable products21% rewritten
- 22We may expend our limited resources to pursue a particular product candidate and fail to capitalize on product candidates that may be more profitable or for which there is a greater likelihood of success
- 23Failure to successfully validate, develop and obtain regulatory approval for companion diagnostics for our product candidates could harm our drug development strategy and operational results46% rewritten
- 24we may not realize the full commercial potential of any product candidates that receive marketing approval if, among other reasons, we are unable to appropriately identify patients with the specific patient selection criteria targeted by our product candidates80% rewritten
- 25more effective, our ability to develop and successfully commercialize product candidates may be adversely affectedNew
- 26Any inability to attract and retain qualified key management and technical personnel would impair our ability to implement our business plan
- 27In addition, job candidates and existing employees often consider the value of the stock awards they receive74% rewritten
- 28We expect we will need to grow our organization in the future, and we may experience difficulties in managing our growth and expanding our operations21% rewritten
- 29Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties24% rewritten
- 30Price controls imposed in either the U.S. or foreign markets may adversely affect our future profitability31% rewritten
- 31Our business entails a significant risk of product liability and our ability to obtain sufficient insurance coverage could have a material and adverse effect on our business, financial condition, results of operations and prospects
- 32Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements23% rewritten
- 33management's attention, governmental investigations, lawsuits, and the expenditure of significant capital and other resourcesNew
- 34Our information technology systems could face serious disruptions that could adversely affect our business
- 35If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be affected adversely
- 36Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences
- 37Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flows, financial condition or results of operations74% rewritten
- 38Our ability to use net operating loss carryforwards to offset taxable income could be limited90% rewritten
- 39Our cash and investments could be adversely affected if the financial institutions in which we hold our cash and investments fail
- 40Our financial results may be adversely affected by changes in accounting principles generally accepted in the United States
Risks Related to Intellectual Property
- 41If we are not able to obtain, maintain and enforce sufficient patent and other intellectual property protection for our technologies or product candidates, development and commercialization of our product candidates may be adversely affected26% rewritten
- 42If we or our licensors or collaborators fail to maintain the patents and patent applications covering our product candidates, our competitors might be able to enter the market, which could have a material and adverse effect on our business, financial condition, results of operations and prospects
- 43If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
- 44Other companies or organizations may challenge our or our licensors’ patent rights or may assert patent rights that prevent us from developing and commercializing our products
- 45We may not be able to protect our intellectual property rights throughout the world81% rewritten
- 46We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our therapeutics
- 47Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities
- 48If we fail to comply with our obligations under any license, collaboration or other agreements, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our product candidates or we could lose certain rights to grant sublicenses40% rewritten
- 49develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitabilityNew
- 50the priority of invention of patented technology
- 51Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time
- 52Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
- 53If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
Risks Related to Government Regulation
- 54We and/or our collaborators may be unable to obtain, or may be delayed in obtaining, U.S. or foreign regulatory approval and, as a result, unable to commercialize our product candidates24% rewritten
- 55meet certain safe-use criteria and requiring treated patients to enroll in a registry. These limitations and restrictions may limit the size of the market for the product and affect reimbursement by third-party payorsNew
- 56Delays in obtaining regulatory approval of our manufacturing process may delay or disrupt our commercialization efforts. To date, no product using a cell-free manufacturing process in the United States has received marketing approval from the FDA
- 57injunctions or the imposition of civil or criminal penalties68% rewritten
- 58We may face difficulties from healthcare legislative reform measures94% rewritten
- 59exclusion from eligibility for the award of government contracts for our products
- 60Our failure to comply with privacy and data security laws, regulations and standards may cause our business to be materially adversely affected
- 61If in the future we are unable to establish U.S. or global sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates, we may not be successful in commercializing our product candidates if they are approved and we may not be able to generate any revenue25% rewritten
- 62Our product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated
- 63If any of our product candidates receives marketing approval and we or others later identify undesirable side effects caused by the product candidates, our ability to market and derive revenue from the product candidates could be compromised48% rewritten
- 64We may also combine the use of our product candidates with other investigational or approved therapies that may cause separate adverse events or events related to the combinationNew
- 65If we decide to seek Fast Track Designation or Breakthrough Therapy Designation by the FDA for any product candidate, even if successful, it may not lead to a faster development or regulatory review or approval process52% rewritten
- 66If we decide to seek Orphan Drug Designation for some of our product candidates, we may be unsuccessful or may be unable to maintain the benefits associated with Orphan Drug Designation, including the potential for orphan drug exclusivity
- 67If we decide to pursue accelerated approval for any of our product candidates, it may not lead to a faster development or regulatory review or approval process and does not increase the likelihood that our product candidates will receive marketing approval
- 68we disseminate false or misleading promotional materials relating to the relevant product candidate70% rewritten
- 69to enhance the balance of access and verification of benefit for therapies available to patients with cancer and hematologic malignanciesNew
Risks Related to Our Common Stock
- 70Our quarterly and annual operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline
- 71Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management
- 72In addition, Section 203 of the DGCL may discourage, delay or prevent a change in control of our company. Section 203 imposes certain restrictions on mergers, business combinations and other transactions between us and holders of 15% or more of our common stock61% rewritten
- 73inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, results of operations and financial conditionNew
- 74Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain
- 75The market price of our stock may be volatile, and you could lose all or part of your investment
- 76general economic, industry and market conditions
- 77If we fail to maintain compliance with Nasdaq’s minimum listing requirements, our common stock will be subject to delisting. Our ability to publicly or privately sell equity securities and the liquidity of our common stock could be adversely affected if our common stock is delistedNew
- 78On December 17, 2025, we regained compliance with Nasdaq Listing Rule 5450(a)(1) following our reverse stock splitNew
- 79The future sale and issuance of equity or of debt securities that are convertible into equity will dilute our share capital
- 80A sale of a substantial number of shares of our common stock may cause the price of our common stock to decline
- 81Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations56% rewritten
- 82If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline
- 83We may be subject to securities litigation, which is expensive and could divert management attention29% rewritten
Other Sutro Biopharma 10-Ks
- FY2024 10-K risk factors81 risks
Sutro Biopharma carries substantial accumulated deficits and relies heavily on unproven cell-free and novel therapeutic platforms.
Filed Mar 13, 2025
About this page
The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.